Clinical-grade generation of peptide-stimulated CMV/EBV-specific T cells from G-CSF mobilized stem cell grafts.

about

Clinical-grade generation of peptide-stimulated CMV/EBV-specific T cells from G-CSF mobilized stem cell grafts.

Item

http://www.wikidata.org/entity/Q55259946

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Clinical-grade generation of p ...... SF mobilized stem cell grafts.

@en

Clinical-grade generation of p ...... SF mobilized stem cell grafts.

@nl

type

Item

label

Clinical-grade generation of p ...... SF mobilized stem cell grafts.

@en

Clinical-grade generation of p ...... SF mobilized stem cell grafts.

@nl

prefLabel

Clinical-grade generation of p ...... SF mobilized stem cell grafts.

@en

Clinical-grade generation of p ...... SF mobilized stem cell grafts.

@nl

P1476

Clinical-grade generation of p ...... CSF mobilized stem cell grafts

@en

P2093

Andreas Mackensen

http://www.w3.org/2001/XMLSchema#string

Anja Gottmann

http://www.w3.org/2001/XMLSchema#string

Armin Gerbitz

http://www.w3.org/2001/XMLSchema#string

Julian Strobel

http://www.w3.org/2001/XMLSchema#string

Jürgen Zingsem

http://www.w3.org/2001/XMLSchema#string

Michael Aigner

http://www.w3.org/2001/XMLSchema#string

Regina Gary

http://www.w3.org/2001/XMLSchema#string

Robert Zimmermann

http://www.w3.org/2001/XMLSchema#string

Stefanie Maas

http://www.w3.org/2001/XMLSchema#string

Stefanie Schaffer

http://www.w3.org/2001/XMLSchema#string

P2860

Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response

HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.

Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.

Selection of CMV-specific CD8+ and CD4+ T cells by mini-EBV-transformed B cell lines.

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Systemic inflammatory response syndrome after administration of unmodified T lymphocytes.

Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT.

Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.

Post-transplant lymphoproliferative disorders.

Presentation of an immunodominant immediate-early CD8+ T cell epitope resists human cytomegalovirus immunoevasion.

P2888

s12967-018-1498-3

P304

124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12967-018-1498-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Andreas Moosmann

Josef Mautner

P577

2018-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1103878247

http://www.w3.org/2001/XMLSchema#string

P698

29743075

http://www.w3.org/2001/XMLSchema#string

P932

5941463

http://www.w3.org/2001/XMLSchema#string